Tell us about your exciting accomplishments!

OVPR staff is excited about the breakthroughs in research and scholarly accomplishments on our campus. If you have been awarded a grant, submitted a paper for publication or been notified that your research is being published in a scholarly journal, please contact us at so we can share the news with the rest of the OUHSC research community.

"The ORA submission process: A review for new investigators"
New PI Training 04-20-16 Final

Other helpful information

On this page, you will also find useful Institutional Data that you may be asked to provide when submitting a proposal.   Please let us know if there is additional information or links you would like to see on our site. Simply complete our Suggestion Form.

ORA Research News - Monday, July 16, 2018

Harold Hamm Diabetes Center (HHDC) - Please mark your calendar for the 15th Annual Harold

Hamm Diabetes Center Research Symposium.  This event will be held on Friday, November 16, 2018 

at the Samis Education Center at Children’s Hospital in Oklahoma City. Deadline for abstracts will be

announced later this summer.  Additional details will be posted on  Questions? 

Please email





NIH Synchronizes Institutional Delegations and Now Allows Decimals in Effort Reporting Field

in Research Performance Progress Reports (RPPR) (NOT-OD-18-202)


Notice of Intent to Publish a Funding Opportunity Announcement for Reproductive Medicine Clinical

Trials Program (R01 Clinical Trial Required) (NOT-HD-18-012)


Notice of Modification to a Page Limitation in PAR-18-266 "Centers of Biomedical Research Excellence

(COBRE)(P20)" (NOT-GM-18-037)


Notice of Modification to a Page Limitation in PAR-18-264 "Limited Competition: Renewal of Centers of

Biomedical Research Excellence (COBRE)(P20)" (NOT-GM-18-038)


Notice of NIMHD Participation in PA-18-343: "Academic Research Enhancement Award (R15 Clinical

Trial Required)" (NOT-MD-18-009)


Notice of Pre-Application Webinar for RFA-CA-18-025 Cooperative Human Tissue Network (CHTN)



Updates for PAR-16-098 "Cooperative Research Agreements Related to World Trade Center Health

Program (U01)" (NOT-OH-18-009)



Please Note:  When only one application is allowed per Institution according to the sponsor

instructions, a one-page letter of intent summarizing the proposed project should be submitted

to the Vice President for Research at least one month prior to the application deadline (unless

otherwise noted).  The letters of intent will be reviewed and a single application will be chosen  

for submission from the University.




Halting TB Transmission in HIV-Endemic and Other High-Transmission Settings (R01 Clinical Trial

Not Allowed) (RFA-AI-18-037) – Deadline December 5, 2018  


The National Health and Aging Trends Study (U01 Clinical Trial Not Allowed) (RFA-AG-19-019)

Deadline October 1, 2018


NIDCD Hearing Healthcare for Adults: Improving Access and Affordability (R21/R33 Clinical Trials

Optional) (RFA-DC-19-001) – Deadline October 4, 2018


NIMH Career Enhancement Award to Advance Autism Services for Adults and Transition-Age Youth

(K18 Clinical Trials Not Allowed) (RFA-MH-19-100) – Deadline October 22, 2018


NIMH Career Enhancement Award to Advance Autism Services for Adults and Transition-Age Youth

(K18 Clinical Trials Required) (RFA-MH-19-101) – Deadline October 22, 2018


Novel Approaches for Characterizing Exposure and Response to Engineered Nanomaterials

(R43 Clinical Trials Not Allowed) (RFA-ES-18-008) – September 11, 2018


Superfund Hazardous Substance Research and Training Program (P42 Clinical Trial Optional)

(RFA-ES-18-002) – December 19, 2018





American Lung Association (ALA) – Lung Cancer Discovery Award – Letter of Intent Deadline

October 3, 2018


ALA – Allergic Respiratory Diseases Award – Deadline December 13, 2018


ALA – Innovation Award – Deadline December 13, 2018


ALA – Catalyst Award – Deadline December 13, 2018


ALA – Public Policy Research Award – Deadline December 13, 2018


ALA – Dalsemer Award – Deadline December 13, 2018



New Clinical Study Opportunities


Please note this is NOT a solicitation for study subjects


Several Pharmaceutical companies are looking for Principal Investigators to participate in the

following clinical studies:



  • Phase 2 Study Is Exploring The Efficacy And Safety Of Various Doses Of Ponatinib

For The Treatment Of Chronic Myeloid Leukemia (CML)

  • Phase III Study Of An Investigational Disease-Modifying, Angiogenic Gene Therapy 

To Treat Patients With Refractory Angina Due To Myocardial Ischemia (00115914)

  • Treating Pediatrics with Secondary Hyperparathyroidism in Chronic Kidney Disease

Undergoing Hemodialysis (Phase 3) 20140315

Please contact Scott Davis at if you would like to receive more information

on any of these studies. The resulting confidentiality and/or clinical study agreement will need to be

routed to the Office of Research Administration.